GlycoMimetics, Inc. (NASDAQ:GLYC) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET

Company Participants

Shari Annes - IR

Harout Semerjian - CEO

Brian Hahn - CFO

Armand Girard - Chief Business Officer

Conference Call Participants

Ed White - H.C. Wainwright

Boris Peaker - Cowen

Roger Song - Jefferies

Zegbeh Jallah - ROTH Capital Partners

Operator

Good morning, and thank you for joining the GlycoMimetics Call. [Operator Instructions]

I’d now like to turn the call over to Shari Annes of Investor Relations Group of GlycoMimetics. Please go ahead.

Shari Annes

Good morning. Today, we will review our accomplishments and financial results for the quarter ended March 31, 2022. The press release we issued this morning is available on the company’s website at www.glycomimetics.com under the Investors tab.

This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investor Relations section of the company’s website.

Joining me on the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; and Armand Girard, Chief Business Officer. We’ll start today’s call with comments from Harout. Brian will follow to provide an overview of the company’s financial position. We’ll then open the call for Q&A.

I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Forward-looking statements on this call may include, but are not limited to, statements about the company’s product candidates, uproleselan, GMI-1687 and other pipeline programs; along with statements about expectations regarding our operations, cash position and data from preclinical studies or clinical trials as well as planned or potential future development, regulatory interactions or submissions and potential commercialization activities or strategic collaborations. Such statements represent management’s judgment and intention as of today and involve assumptions, risks and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to GlycoMimetics’ filings with the SEC, which are available from the SEC or on the GlycoMimetics website.

I’ll now turn the call over to Harout.

Harout Semerjian

Thank you, Shari, and good morning, everyone. In our year-end call 8 weeks ago, we shared our outlook and strategy for the year ahead. We have provided updates on both our regulatory and commercial readiness activities, all designed to advance GlycoMimetics and our lead program, uproleselan, with a focus towards commercialization.